Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Zimmer Biomet reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

ZBH exhibits high volatility around earnings releases, with an average absolute Day 0 move of 7.68%—significantly larger than typical healthcare stocks. The direction has been mixed, with four positive and four negative Day 0 reactions over the past eight quarters, though the magnitude of negative moves has been particularly severe. The November 2025 report triggered a -15.15% decline, while April 2026's -10.57% drop demonstrates the stock's vulnerability to disappointment despite beating estimates.

The Day +1 follow-through averages 2.36%, suggesting initial reactions often extend into the second session. Notably, several large Day 0 declines were followed by modest Day +1 recoveries, indicating investors sometimes reassess after digesting the full earnings details. The current options market is pricing a 6.88% expected move, which sits below the historical 7.68% average Day 0 move, suggesting options traders may be underestimating potential volatility based on recent history.

Part 2.2: Options Market Expected Move

The options market's 6.88% expected move is notably lower than the stock's 7.68% average historical Day 0 move, suggesting options may be underpricing potential volatility. Given ZBH's track record of large post-earnings swings—including moves exceeding 10% in three of the past eight reports—the current implied move appears conservative.

Part 3: What Analysts Are Saying

Analyst sentiment toward Zimmer Biomet remains cautious with a "Hold" consensus. Among 29 analysts covering the stock, 7 rate it a Strong Buy, 1 a Moderate Buy, 18 assign Hold ratings, and 3 rate it a Strong Sell. The average recommendation of 3.31 on the five-point scale reflects a neutral-to-slightly-positive stance, though this represents a slight deterioration from 3.33 one month ago.

The consensus price target of $97.75 implies just 2.0% upside from the current price of $95.81, suggesting analysts see limited near-term appreciation potential. However, the wide range of targets—from a low of $83.00 to a high of $125.00—reveals significant disagreement about the company's prospects. The Street-high target implies 30.4% upside for bulls who believe ZBH can successfully navigate its challenges and capitalize on its market position.

Sentiment has deteriorated over the past month, with one analyst downgrading from Hold to Strong Sell. This shift reflects growing concerns about organic growth challenges, competitive pressures in robotic surgery, and the integration risks associated with the Paragon 28 acquisition. The concentration of ratings in the Hold category—representing 62% of coverage—suggests most analysts are taking a wait-and-see approach, wanting evidence that management can deliver on its raised guidance before becoming more constructive.

Part 4: Technical Picture

Zimmer Biomet enters earnings with strengthening technical momentum after a notable shift in the Barchart Technical Opinion. The signal currently stands at 56% Buy, a dramatic improvement from 24% Buy one week ago and a complete reversal from the 48% Sell reading one month ago. This rapid strengthening suggests growing technical conviction as the stock has rallied into the earnings release.

The stock is trading at $95.81, above all major moving averages, indicating broad-based technical strength across timeframes. ZBH sits above its 5-day ($95.77), 10-day ($93.63), 20-day ($92.16), 50-day ($89.15), 100-day ($88.87), and 200-day ($91.08) moving averages. This alignment with the stock above all key averages is a bullish configuration that suggests momentum has shifted decisively positive heading into the report.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum and suggests the stock is in a strong uptrend on an immediate basis
• Medium-term (Hold): Neutral reading suggests the intermediate trend is consolidating, providing neither strong support nor resistance
• Long-term (50% Buy): Moderate positive signal reflects improving sentiment in the longer-term trend structure

Trend Characteristics: The trend is characterized as Soft in strength but Strengthening in direction, suggesting momentum is building but not yet firmly established—a setup that could amplify volatility around earnings as the nascent uptrend faces its first major test.

The technical setup heading into earnings is supportive but vulnerable to reversal. While the stock's position above all moving averages and the 100% short-term buy signal provide a bullish foundation, the "Soft" trend strength indicates this momentum lacks deep conviction. The 50-day moving average at $89.15 represents the first major support level, approximately 7% below current prices—roughly in line with the options market's expected move. Given the stock's history of large post-earnings swings and the recent rapid improvement in technical signals, ZBH is positioned for either a breakout continuation above resistance or a sharp reversal if results disappoint. The proximity to the mean analyst price target of $97.75 suggests limited cushion for error, making execution on guidance and commentary about pricing pressures critical to maintaining the technical momentum.